Outsourcing

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

Articles

The industry will see an impact from financing, M&As, advanced therapies, generic drugs, and the retail market in 2018.

What to Watch for in 2018

Susan Haigney is lead editor of Pharmaceutical Technology and Pharmaceutical Technology Europe.

In a productive year, 2017 was filled with acquisitions, facility expansions, and new biopharma technology. 

Pharma Outsourcing: A Year in Review

Outsourcing: A Year in Review

Recent acquisitions are creating CDMOs with scale that rivals global bio/pharma.

CDMO Acquisitions Build Strategic Supplier Base

Mergers and acquisitions are positive for the CDMO industry, but there is a downside.

Up and Away, M&A

Matching the production requirements of a bio/pharma company with the manufacturing capabilities of a CMO is a delicate balance, requiring attitude shifts on both sides of the table.


Flexibility and Innovation Needed to Solve Manufacturing Uncertainity

Ronald A. Rader is senior director, Technical Research, at BioPlan Associates.

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Innovation speeds discovery, drives down costs, and improves productivity.

Top Trends in Biopharmaceutical Manufacturing, 2017

Gil Roth is president of the Pharma & Biopharma OutsourcingAssociation, gil.roth@pharma-bio.org.

Despite some progress, the industry is still in a wait-and-see mode regarding the administration, Congress, and FDA.

CDMOs: New Administration, New Frontier

How has the bio/pharmaceutical contract manufacturing industry evolved over the years and what does the future hold?

Contract Manufacturing Through the Years

Kathleen A. Estes, PhD, is director of research communications atBioPlan Associates, Inc. She is an experienced market research and data trends analyst, author, and editor, kestes@bioplanassociates.com.

Although widespread adoption of continuous bioprocessing has been slow, some processes have been an exception.

Outsourcing Outlook